PROJECT AEROVIA-CF1A
Candidate Nomination Dossier
Program Code: SCF-CF-S5-0001
Indication: Cystic Fibrosis
Development Pathway: Adjunctive Disease-Modifying Therapy
Regulatory Classification: New Chemical Entity (505(b)(1) NDA Pathway)
I. STAGE 5 EXECUTIVE DECISION
Following Stage 4 evaluation, candidate prioritization is narrowed to:
Lead Candidate
AEROVIA-CF1A-201
(TCP-201 Derived Program)
Localized Pulmonary Neutrophil Elastase Modulator
Backup Candidate
AEROVIA-CF1A-101
(TCP-101 Derived Program)
Anti-Biofilm Pulmonary Therapeutic
Future Combination Strategy
AEROVIA-CF1A-COMBO
- Elastase Modulation
- Anti-Biofilm Activity
- Fibrosis Prevention
Integrated into a single inhaled platform.
II. LEAD CANDIDATE NOMINATION PACKAGE
Candidate Code
AEROVIA-CF1A-201
Therapeutic Class
Selective Pulmonary Neutrophil Elastase Inhibitor
Intended Clinical Position
Add-on therapy to:
Trikafta
and future CFTR modulators.
Clinical Rationale
Persistent neutrophilic inflammation remains one of the strongest predictors of progressive lung decline despite CFTR correction.
Major downstream consequences:
- Protease-mediated tissue destruction
- Bronchiectasis progression
- ECM degradation
- Fibrotic remodeling
A localized pulmonary elastase inhibitor directly addresses this residual disease driver.
III. TARGET PRODUCT PROFILE (FINALIZED VERSION 1.0)
Parameter | Target |
Indication | Cystic Fibrosis |
Population | Adolescent and adult CF |
Route | Inhaled |
Dosing Frequency | Once Daily |
Mechanism | Elastase modulation |
Therapy Type | Adjunctive |
Duration | Chronic |
Safety Objective | Minimal systemic exposure |
IV. PRECLINICAL DEVELOPMENT PLAN
Module A — Pharmacology
Primary Objective
Demonstrate reduction of elastase-mediated tissue injury.
Required Assays
Assay | Endpoint |
Elastase enzyme assay | IC50 |
Human neutrophil assay | Functional inhibition |
Airway epithelial assay | Cytoprotection |
Lung organoid model | Tissue preservation |
Module B — Disease Models
In Vitro CF Models
Human bronchial epithelial cultures.
Measurements:
- IL-8
- Elastase activity
- Cell viability
- Mucus characteristics
Biofilm Co-Culture Models
Pathogens:
- Pseudomonas aeruginosa
- Staphylococcus aureus
Measurements:
- Inflammatory signaling
- Neutrophil recruitment
- Tissue injury
V. IND-ENABLING TOXICOLOGY PACKAGE
Following FDA IND requirements.
Safety Pharmacology
Required systems:
Respiratory
- Airway reactivity
- Pulmonary function
Cardiovascular
- ECG
- Blood pressure
- QT assessment
CNS
- Behavioral observations
- Neurotoxicity screen
Repeat-Dose Toxicology
Species 1
Rat
Species 2
Dog or non-rodent inhalation species
Duration
Study | Duration |
Range finding | 14 days |
IND enabling | 28 days |
Chronic support | 90 days |
VI. CMC DEVELOPMENT PACKAGE
Drug Substance
Requirements:
- Synthetic route established
- Impurity profile characterized
- Stability indicating methods developed
Drug Product
Preferred formulation:
Dry Powder Inhalation
Backup:
Nebulized Liposomal Suspension
CMC Milestones
Milestone | Objective |
Route selection | Final synthesis |
Analytical methods | Release testing |
Stability program | Shelf life |
Scale-up | GMP readiness |
VII. TRANSLATIONAL BIOMARKER PANEL
Primary Biomarkers
Biomarker | Purpose |
Neutrophil elastase | Target engagement |
IL-8 | Inflammatory activity |
MMP-9 | Tissue injury |
CRP | Systemic inflammation |
Clinical Endpoints
Phase I
- Safety
- PK
- Sputum elastase reduction
Phase II
- FEV1
- Exacerbation rate
- Lung Clearance Index
Phase III
- Pulmonary decline rate
- Hospitalization frequency
- Quality of life
VIII. REGULATORY STRATEGY
FDA Designations
Potential opportunities:
Orphan Drug Designation
Strongly applicable.
Fast Track Designation
Potentially applicable.
Breakthrough Therapy
Possible if significant biomarker and clinical improvements are demonstrated.
IX. PRE-IND PACKAGE OUTLINE
Section 1
Disease Background
- CF residual disease burden
- Unmet clinical need
Section 2
Mechanism
- Neutrophil elastase biology
- Residual disease pathology
Section 3
Preclinical Pharmacology
- In vitro efficacy
- In vivo efficacy
Section 4
Toxicology
- Safety package
- Pulmonary safety
Section 5
CMC
- Manufacturing process
- Formulation strategy
X. FIRST-IN-HUMAN BLUEPRINT
Phase I
Population
Adult CF patients
Objectives
- Safety
- Tolerability
- PK
Exploratory Endpoints
- Elastase reduction
- IL-8 reduction
Phase IIa
Population
CF patients receiving CFTR modulators
Objectives
- Proof of mechanism
- Proof of concept
Primary Endpoint
Change in sputum elastase activity.
XI. SCF PRECLINICAL CANDIDATE NOMINATION
Nomination Outcome
Selected Candidate
AEROVIA-CF1A-201
Localized Pulmonary Elastase Modulator
Scientific Justification
Highest ranking based upon:
Criterion | Score |
Biological rationale | High |
Translational tractability | High |
Biomarker availability | High |
Regulatory feasibility | High |
Manufacturing feasibility | Moderate–High |
Differentiation potential | High |
XII. STAGE 5 DECISION GATE
Criterion | Outcome |
Candidate Selected | PASS |
Target Product Profile Defined | PASS |
IND Strategy Defined | PASS |
Toxicology Plan Defined | PASS |
Biomarker Plan Defined | PASS |
Clinical Translation Plan Defined | PASS |
STAGE 5 OUTCOME
ADVANCE TO STAGE 6 — PRECLINICAL EXECUTION & CANDIDATE VALIDATION
Stage 6 Objectives
- Experimental lead validation
- Medicinal chemistry optimization
- PK/PD characterization
- GLP toxicology execution
- GMP process development
- IND package assembly
- FDA pre-IND interaction
Important Development Boundary
From Stage 6 onward, progression requires real-world experimental evidence. Computational frameworks, SCF logic, and mechanistic hypotheses can prioritize candidates, but efficacy, safety, and regulatory advancement must be established through laboratory, animal, manufacturing, and clinical studies.
MASTER REGISTRY INDEX
SCF-CF-S5-0001 — Preclinical Candidate Nomination & IND-Enabling Strategy
SCF-CF-AEROVIA-201 — Lead Candidate Nomination Program
SCF-FDA-IND-0001 — IND Development Framework
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-PATH-UT-0001 — SCF Pathophysiology Protocol
SCF-PCR-0001 — Preventative–Curative–Restorative Architecture
SCF-CMC-0001 — Chemistry, Manufacturing & Controls Development Framework